{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:54:25Z","timestamp":1765356865041,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.intimp.2021.107404","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T05:44:06Z","timestamp":1611985446000},"page":"107404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane"],"prefix":"10.1016","volume":"93","author":[{"given":"Annelieke E.C.A.B.","family":"Willemsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"van Cranenbroek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.P.M.","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M.L.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2021.107404_b0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"4","key":"10.1016\/j.intimp.2021.107404_b0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.clpt.6100317","article-title":"Rapamycin: something old, something new, sometimes borrowed and now renewed","volume":"82","author":"Hartford","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2021.107404_b0015","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers3022478","article-title":"Targeting the mammalian target of rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives","volume":"3","author":"Dufour","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2021.107404_b0020","unstructured":"Everolimus, Highlights of prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022334s040,203985s013lbl.pdf (accessed: 27th October 2019)."},{"issue":"5","key":"10.1016\/j.intimp.2021.107404_b0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107404_b0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0394632017734459","article-title":"Immunological effects of everolimus in patients with metastatic renal cell cancer","volume":"30","author":"Huijts","year":"2017","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107404_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2016.05.005","article-title":"Differential effects of inhibitors of the PI3K\/mTOR pathway on the expansion and functionality of regulatory T cells","author":"Huijts","year":"2016","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2021.107404_b0040","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107404_b0045","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2006101143","article-title":"Regulatory T cells and T cell depletion: role of immunosuppressive drugs","volume":"18","author":"Noris","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107404_b0050","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.tp.0000284808.28353.2c","article-title":"Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury","volume":"84","author":"Ruggenenti","year":"2007","journal-title":"Transplantation"},{"issue":"14","key":"10.1016\/j.intimp.2021.107404_b0055","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1158\/0008-5472.CAN-15-2452","article-title":"Rapalogs efficacy relies on the modulation of antitumor T-cell immunity","volume":"76","author":"Beziaud","year":"2016","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2021.107404_b0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/bjc.2011.15","article-title":"Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines","volume":"104","author":"Wang","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2021.107404_b0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CJI.0000000000000006","article-title":"Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma","volume":"37","author":"Thiery-Vuillemin","year":"2014","journal-title":"J. Immunother."},{"issue":"20","key":"10.1016\/j.intimp.2021.107404_b0070","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1158\/0008-5472.CAN-16-0091","article-title":"Immune-stimulatory effects of rapamycin are mediated by stimulation of antitumor gammadelta T cells","volume":"76","author":"Dao","year":"2016","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2021.107404_b0075","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/annonc\/mdu021","article-title":"Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107404_b0080","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/ijc.29887","article-title":"mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm","volume":"138","author":"Willemsen","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2021.107404_b0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00007890-200109150-00008","article-title":"Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients","volume":"72","author":"Morelon","year":"2001","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.intimp.2021.107404_b0090","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","article-title":"Sirolimus-associated pulmonary toxicity","volume":"77","author":"Pham","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.intimp.2021.107404_b0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","article-title":"The TSC-mTOR signaling pathway regulates the innate inflammatory response","volume":"29","author":"Weichhart","year":"2008","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.intimp.2021.107404_b0100","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","article-title":"The multifunctional role of mTOR in innate immunity: implications for transplant immunity","volume":"9","author":"Saemann","year":"2009","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.intimp.2021.107404_b0105","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.celrep.2016.10.053","article-title":"Differential effects of environmental and genetic factors on T and B cell immune traits","volume":"17","author":"Aguirre-Gamboa","year":"2016","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.intimp.2021.107404_b0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2021.107404_b0115","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","article-title":"Phenotypic and functional separation of memory and effector human CD8+ T cells","volume":"186","author":"Hamann","year":"1997","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107404_b0120","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41598-019-39345-5","article-title":"Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment","volume":"9","author":"Iwahori","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2021.107404_b0125","first-page":"316","article-title":"Activated CD8+ T cells and natural killer T cells in bronchoalveolar lavage fluid in hypersensitivity pneumonitis and sarcoidosis","volume":"31","author":"Tondell","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"4","key":"10.1016\/j.intimp.2021.107404_b0130","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1378\/chest.07-0128","article-title":"Expansion of pulmonary CD8+CD56+ natural killer T-cells in hypersensitivity pneumonitis","volume":"132","author":"Korosec","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.intimp.2021.107404_b0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/resp.12305","article-title":"Bronchoalveolar lavage fluid and blood natural killer and natural killer T-like cells in cryptogenic organizing pneumonia","volume":"19","author":"Papakosta","year":"2014","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.intimp.2021.107404_b0140","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.4049\/jimmunol.1402710","article-title":"mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells","volume":"195","author":"Huijts","year":"2015","journal-title":"J. Immunol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2021.107404_b0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12026-012-8297-3","article-title":"The three human monocyte subsets: implications for health and disease","volume":"53","author":"Wong","year":"2012","journal-title":"Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2021.107404_b0150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.clim.2008.09.011","article-title":"Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients","volume":"130","author":"Moniuszko","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2021.107404_b0155","article-title":"Everolimus-related pneumonitis in patients with metastatic breast cancer: incidence, radiographic patterns, and relevance to clinical outcome","author":"Gong","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.intimp.2021.107404_b0160","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bju.12420","article-title":"Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes","volume":"113","author":"Atkinson","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.intimp.2021.107404_b0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2017.05.004","article-title":"Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma","volume":"81","author":"Penttila","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2021.107404_b0170","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2021.107404_b0175","doi-asserted-by":"crossref","first-page":"e5994","DOI":"10.1371\/journal.pone.0005994","article-title":"Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin","volume":"4","author":"Strauss","year":"2009","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2021.107404_b0180","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4049\/jimmunol.178.1.320","article-title":"Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin","volume":"178","author":"Strauss","year":"2007","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107404_b0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2478\/v10007-012-0012-3","article-title":"Immunomodulatory effects of anti-estrogenic drugs","volume":"62","author":"Ray","year":"2012","journal-title":"Acta. Pharm."},{"issue":"7","key":"10.1016\/j.intimp.2021.107404_b0190","first-page":"1211","article-title":"Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents","volume":"29","author":"Watanabe","year":"2002","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"10.1016\/j.intimp.2021.107404_b0195","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/1078-0432.CCR-08-1507","article-title":"Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients","volume":"15","author":"Generali","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.107404_b0200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-017-4570-4","article-title":"Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer","volume":"168","author":"Kwa","year":"2018","journal-title":"Breast Cancer Res. Treat."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:29:13Z","timestamp":1761586153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":40,"alternative-id":["S1567576921000400"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107404","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107404"}}